Why the study?
Does T2 mapping predict cardiovascular events in adult patients with hypertrophic cardiomyopathy?
Does T2 mapping predict cardiovascular events in adult patients with hypertrophic cardiomyopathy?
Answers are grounded in this paper and cite their sources.
Parametric mapping, specifically T2 max, may have a supplementary role in predicting overall cardiovascular events in patients with HCM and LGE, improving risk stratification models.
This editorial refers to ‘Incremental significance of myocardial oedema for prognosis in hypertrophic cardiomyopathy’, by Z. Xu et al., https://doi:10.1093/ehjci/jead065. Hypertrophic cardiomyopathy (HCM) is a heart muscle disease characterized by left ventricular hypertrophy unexplained solely by abnormal loading conditions.1 Patients with HCM experience higher mortality rates compared with the general population, but the progression and severity of the condition vary greatly among individuals. Although sudden cardiac death (SCD) is a rare event in the short to medium term, it is the prevailing cause of death in younger individuals with HCM. In older patients, stroke associated with atrial fibrillation and heart failure (HF) account for most of the excess morbidity and mortality.2 Many observational and mainly retrospective studies have been conducted to identify major clinical risk markers in HCM with the aim of guiding intervention with implantable cardioverter defibrillators (ICDs).1,3 Clinical features associated with an increased risk for SCD include various components of medical and family history, as well as parameters obtained from cardiovascular imaging and ambulatory electrocardiogram monitoring. Xu et al.4 explore the role of T2 mapping as a potential marker of adverse prognosis in HCM by studying an observational cohort of 674 adult patients and 100 controls who underwent cardiovascular magnetic resonance (CMR). Compared with healthy individuals, HCM patients had elevated T2 max, T2 min, and T2 global values. Patients with HCM and late gadolinium enhancement (LGE) exhibited higher global T2 values when compared with those without LGE. The increase in T2 values among HCM patients was not limited to segments with LGE. During a median follow-up of 36 months (interquartile range: 24–60 months), 55 patients (8.2%) had cardiovascular events: 4% received appropriate ICD treatment, 2.2% experienced SCD, and 1.9% HF-associated death. Patients with cardiovascular events tended to be older and had a higher prevalence of non-sustained ventricular tachycardia and a left ventricular ejection fraction (LVEF) of <50% as well as a larger left atrial size and more widespread LGE. They also tended to have higher T2-STIR signal, T2 max, T2 min, and T2 global values, as well as higher native T1 and extracellular volume (ECV) values. Survival analysis showed that higher T2 max in patients with LGE was associated with increased risk of developing the composite endpoint. In contrast, higher T2 max in patients without LGE did not correlate with increased risk for adverse events compared with individuals with lower values. Using multivariable Cox proportional hazards models to compare outcomes, among the various factors analysed, ESC risk score, LVEF < 50%, extensive LGE, elevated T2 max, T2 min, and T2 global values were identified as independent predictors of cardiovascular events. Incorporating T2 max into a predictive model based on ESC score, LVEF < 50%, and extensive LGE led to an improved model performance with a C-index of 0.825. The HCM phenotype extends beyond mere hypertrophy and includes myocardial ischaemia, fibrosis, and myocyte disarray. Several studies have suggested that myocardial scar burden as measured by CMR imaging is a predictor of adverse outcomes in HCM, but a number of unsolved questions remain including the inevitable confounders in retrospective studies that bias towards high-risk patients and the methods used to quantify LGE. In a large prospective study of 2755 patients (HCMR), LGE was present in 50% of patients based on visual criteria but in the most recent report from the registry, there have been only 24 deaths from any cause after a mean follow-up of 33.5 ± 12.4 months.5 T2 lengthening is caused by different mechanisms, such as an increase in water content through the transfer of water molecules from the extracellular to the intracellular space or an increase in the ratio of free to protein-bound water. On the other hand, interstitial oedema occurs when capillary membranes become permeable to complex molecules, and its expansion is reflected in ECV rather than just T2 values.6 The proposed mechanism for the increased T2 signal in HCM is that microvascular dysfunction and subsequent ischaemia cause alterations in myocardial water state and net water content. As yet, there are only limited data on the role of inflammation in HCM, and its significance in this context remains uncertain. The results in this study are in keeping with previous studies using parametric mapping to characterize myocardial tissue properties. Native T1 has the potential to identify areas of tissue pathology beyond those detected by LGE in HCM and T1 and T2 values are elevated in both hypertrophied and non-hypertrophied segments.7–9 Xu et al. suggest that T2 values in HCM may have a supplementary role in predicting overall cardiovascular events in patients with HCM and LGE, but while hypothesis-generating, these data must be interpreted with caution given the unusually high event rate in their study which suggests a degree of ascertainment bias. In addition, the examination of a relatively large number of variables in a small cohort introduces a significant risk of data overfitting and statistical optimism.10 Another limitation is the lack of genetic data at baseline that could potentially inform about the impact of genotype on parametric mapping and provide further mechanistic insights. With the emergence of new therapies for HCM, the search for novel risk predictors will continue in order to identify patient subgroups that may benefit from early intervention. Once more, this study shows that well-established clinical risk markers and clinical scores demonstrate reasonable performance. Nonetheless, parametric mapping has the potential to add value by examining the role of ischaemia and oedema, thus providing further a mechanistic understanding of potential arrhythmia triggers. No new data associated with this invited editorial.
No takes yet. Share an insight, caveat, or question.
Bakalakos et al. (2023) conducted an editorial in Hypertrophic cardiomyopathy (n=774). Elevated T2 mapping values (T2 max) vs. Lower T2 values was evaluated on Cardiovascular events.
Synapse has enriched 10 related papers. Consider them for comparative context: